Q-omics provides the consensus-scored PRSS23 profile across patient tissues and cancer cell-line models. PRSS23 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRSS23 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PRSS23 RNA expression shows 22,715 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where PRSS23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS23 survival associations across molecular data types. PRSS23 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS23 RNA expression–survival associations across cancer types. High PRSS23 expression shows unfavorable associations in KIRP, HNSC, MESO, ACC and LGG, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRSS23 RNA expression.
This table summarizes PRSS23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PRSS23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS23 shows lower tumor expression in BLCA and higher tumor expression in HNSC, KIRC, THCA, BRCA and CHOL. The HNSC box plot shows higher PRSS23 RNA expression in tumor versus normal tissue (log2 FC = +2.164, t-test p < 0.001).
This table shows molecular features associated with PRSS23 in patient tissues and cancer cell lines. In patient samples, PRSS23 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
